QuadMedicine Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-5,485	-4,968	-9,759
Depreciation & Amortization	3,312	3,153	2,071
Stock-Based Compensation	389.32	608.42	1,456
Other Operating Activities	-198.63	-128.87	40.43
Change in Accounts Receivable	-1,399	-1,082	-6.41
Change in Other Net Operating Assets	-3,157	3,490	7,957
Operating Cash Flow	-5,650	1,072	1,760
Operating Cash Flow Growth	-	-39.09%	-
Capital Expenditures	-1,894	-3,286	-11,817
Sale (Purchase) of Intangibles	-206.87	-218.8	-95.1
Investment in Securities	-1,415	-10	4,760
Other Investing Activities	-38.77	66.23	-134.66
Investing Cash Flow	-3,554	-3,449	-7,286
Short-Term Debt Issued	-	500	-
Long-Term Debt Issued	-	800	5,800
Total Debt Issued	-	1,300	5,800
Long-Term Debt Repaid	-	-313.44	-271.52
Net Debt Issued (Repaid)	-351.31	986.56	5,528
Issuance of Common Stock	7,968	7,000	537.1
Other Financing Activities	74.04	74.04	196.28
Financing Cash Flow	7,691	8,061	6,262
Foreign Exchange Rate Adjustments	70.54	129.9	20.89
Net Cash Flow	-1,443	5,814	757.16
Free Cash Flow	-7,544	-2,214	-10,056
Free Cash Flow Margin	-57.54%	-23.80%	-993.97%
Free Cash Flow Per Share	-815.09	-253.98	-1164.44
Cash Interest Paid	370.93	368.76	64.9
Cash Income Tax Paid	5.91	-17.81	4.46
Levered Free Cash Flow	-8,731	-2,182	-
Unlevered Free Cash Flow	-8,501	-1,951	-
Change in Working Capital	-3,668	2,408	7,951

Source: S&P Global Market Intelligence. Standard template. Financial Sources.